Alirocumab's Price Reduction

Circulation. 2018 Oct 9;138(15):1502-1504. doi: 10.1161/CIRCULATIONAHA.118.036069.
No abstract available

Keywords: cardiovascular diseases; cost-benefit analysis; costs and cost analysis; insurance, health, reimbursement; outcome and process assessment (health care).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents / economics*
  • Commerce / economics*
  • Cost-Benefit Analysis
  • Drug Costs*
  • Drug Industry / economics*
  • Health Services Accessibility / economics*
  • Humans

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • alirocumab